Academic literature on the topic 'Neuromuscular diseases Diagnosis'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Neuromuscular diseases Diagnosis.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Journal articles on the topic "Neuromuscular diseases Diagnosis"
Younger, David S., and Paul H. Gordon. "DIAGNOSIS IN NEUROMUSCULAR DISEASES." Neurologic Clinics 14, no. 1 (February 1996): 135–68. http://dx.doi.org/10.1016/s0733-8619(05)70247-4.
Full textMary, P., L. Servais, and R. Vialle. "Neuromuscular diseases: Diagnosis and management." Orthopaedics & Traumatology: Surgery & Research 104, no. 1 (February 2018): S89—S95. http://dx.doi.org/10.1016/j.otsr.2017.04.019.
Full textMusteață, Mihai. "Diagnosis and management of neuromuscular diseases." Practica Veterinara.ro 4, no. 33 (2018): 25. http://dx.doi.org/10.26416/pv.33.4.2018.2104.
Full textMaruyama, Rika, and Toshifumi Yokota. "Molecular Diagnosis and Novel Therapies for Neuromuscular Diseases." Journal of Personalized Medicine 10, no. 3 (September 16, 2020): 129. http://dx.doi.org/10.3390/jpm10030129.
Full textAngelini, Corrado. "Neuromuscular diseases: advances in therapy and diagnosis." Lancet Neurology 11, no. 1 (January 2012): 15–17. http://dx.doi.org/10.1016/s1474-4422(11)70271-x.
Full textCamilleri, Michael. "Diagnosis and treatment of enteric neuromuscular diseases." Clinical Autonomic Research 13, no. 1 (February 1, 2003): 10–15. http://dx.doi.org/10.1007/s10286-003-0073-y.
Full textLobzin, V. S. "Paroxismal states in neuromuscular diseases." Neurology Bulletin XXV, no. 1-2 (September 20, 1993): 77–80. http://dx.doi.org/10.17816/nb105961.
Full textRivas, E., A. Sáez, A. Montero-Sánchez, C. Paradas, B. Acha, A. Pascual, C. Serrano, and L. Escudero. "Quantifiable diagnosis of neuromuscular diseases through network analysis." Neuromuscular Disorders 25 (October 2015): S243. http://dx.doi.org/10.1016/j.nmd.2015.06.211.
Full textHodgkinson, V., J. Lounsberry, S. M’Dahoma, A. Russell, G. Jewett, T. Benstead, B. Brais, et al. "The Canadian Neuromuscular Disease Registry 2010–2019: A Decade of Facilitating Clinical Research Througha Nationwide, Pan-NeuromuscularDisease Registry." Journal of Neuromuscular Diseases 8, no. 1 (January 1, 2021): 53–61. http://dx.doi.org/10.3233/jnd-200538.
Full textFernandes, Isabella Araujo Mota, Renata Oliveira Almeida Menezes, and Guilhermina Rego. "EMPATIA: A Guide for Communicating the Diagnosis of Neuromuscular Diseases." International Journal of Environmental Research and Public Health 19, no. 16 (August 9, 2022): 9792. http://dx.doi.org/10.3390/ijerph19169792.
Full textDissertations / Theses on the topic "Neuromuscular diseases Diagnosis"
Braida, Claudia. "Molecular analysis of myotonic dystrophy type 1 patients with an unusual molecular diagnosis." Thesis restricted. Connect to e-thesis to view abstract, 2008. http://theses.gla.ac.uk/359/.
Full textPh.D. thesis submitted to the Division of Molecular Genetics, Institute of Biomedical and Life Sciences, University of Glasgow, 2008. Includes bibliographical references. Print version also available.
Maile, Charlotte Amy. "Pathophysiology of equine type1 polysaccharide storage myopathy." Thesis, Royal Veterinary College (University of London), 2013. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.618291.
Full textKuschel, Franziska. "Die medizinische Versorgung erwachsener Patienten mit Muskelerkrankungen." Doctoral thesis, Humboldt-Universität zu Berlin, Medizinische Fakultät - Universitätsklinikum Charité, 2006. http://dx.doi.org/10.18452/15466.
Full textIn spring/summer 2002 a group of 51 adult patients in Berlin-Brandenburg suffering from a muscle or a neuromuscular disease were questioned concerning various aspects of their medical care. The applied methods were a standardized questionnaire and a qualitative interview. The average time between the first consultation of a physician and the establishment of the diagnosis of a muscle disease was 4,1 years (median: 1 year). 59% of the patients received their diagnosis at a hospital. An insufficient history-taking, lacks in the physical examination and a reluctance to refer the patient to a neurologist could be identified. There was a significant delay for those patients who initially consulted a non-neurological specialist instead of a general physician. 43% of the patients had difficulties in finding a qualified physician for the long-time care. The patients were insufficiently informed about the heredity of their disease and about possible respiratory and cardiac complicati! ons. There was a lack in following up the respiratory and cardiac functions of the patients. The prescription of physiotherapy and aids was rated positively by the patients. 51% of the patients had hospital stays also after having their diagnosis. 22% were admitted to hospital due to complications of their disease. In general, deficits in the medical care for these patients were shown, similar to those described in expert opinions or few preview studies. A specialized hospital-based outpatient centre that should ensure the specialized multidisciplinary care for the patients is regarded as the model for the medical care in the area of rare diseases. Similar centres exist in Germany by now, but there are no outcome-studies yet.
"Metabolomic strategies for early diagnosis of myasthenia gravis and efficacy evaluation of Qiangji Jianli Fang." 2013. http://library.cuhk.edu.hk/record=b5549768.
Full text本研究所用樣本來自42個重症肌無力病人和16個健康志願者。樣本由廣州中醫藥大學第一附屬醫院於二零零七年到二零零八年收集所得。診斷後,病人每日口服一定劑量的強肌健力方接受治療,連續服藥兩個月。分別在服藥前和治療後對病人抽血採樣。進一步分離血清後,樣品進行質譜分析。多元統計學方法如主成分分析,正交偏最小二乘和正交偏最小二乘判別分析等用於質譜數據的分析。
通過和健康者比較分析,我們在重症肌無力病人的血液中找到142個顯著改變的離子。其中,14個離子得到鑒定,包括:γ-氨基丁酸,2-哌啶酸,鳥氨酸,5,8-十四碳二羧酸,精胺,己酰肉毒鹼,N-油酰基甘氨酸,鞘氨醇-1-磷酸,聯原膽酸,糞甾烷酸,植物鞘氨醇-1-磷酸,鵝去氧膽酸甘氨酸結合物,輔酶Q4和甘氨酸膽。基於以上142個離子建立的數學診斷模型在診斷重症肌無力時表現出很高的靈敏度和特異性,分別高達92.8%和83.3%。強肌健力方能夠逆轉由重症肌無力引起的特異性代謝變化,將病人體內被改變的代謝網絡恢復正常,特別是大部分的代謝標誌物在治療後都恢復到了相對正常水平,包括:γ-氨基丁酸,哌啶酸,鳥氨酸,5,8-十四碳二羧酸,精胺,己酰肉毒鹼,N-油酰甘氨酸,鞘氨醇-1-磷酸,聯原膽酸,輔酶Q4和甘氨酸膽。
本研究揭示了基於液質聯用的代謝組學方法適用於探索重症肌無力的代謝標誌物,並提供了一種可用於診斷重症肌無力的新方法。同時,本研究證實強肌健力方適用於重症肌無力的治療,且無明顯副作用。
Myasthenia gravis (MG) is an acquired autoimmune disease caused by specific autoantibodies against acetylcholine receptors (AChRs) and muscle-specific kinase (MuSK) proteins at the neuromuscular junctions. The disease is characterized by weakness and fatigability of the voluntary muscles that gets worse with exertion and improves with rest. The global incidence rate of MG is about 3-30 cases per million per year. In recent years, the worldwide prevalence rate of MG is increasing as a result of increased awareness. However, current diagnostic measures and treatments are not conclusive and satisfactory for MG. In this study, a mass spectrometry-based metabolomic strategy was applied to develop a novel and reliable diagnostic measure for MG on the basis of metabolic analysis, and to explore the therapeutic effect of Qiangji Jianli Fang (QJF, a newly developed Chinese medicine formula) on MG at the metabolite level.
Total 42 MG patients (13 males and 29 females) and 16 volunteers (5 males and 11 females) were recruited at the First Affiliated Hospital of Guangzhou University of Chinese Medicine between March 2007 and March 2008. The patients took QJF once per day for 2 months. Peripheral blood from patients was collected at diagnosis and after 2-month treatment, respectively. Sera prepared from the blood samples were monitored by the liquid chromatography Fourier transform mass spectrometry (LC-FTMS). Mass spectral data were analyzed by multivariate statistical analyses, including principal component analysis (PCA), orthogonal partial least squares (OPLS), and orthogonal partial least squares discriminant analysis (OPLS-DA).
By comparing analysis with the healthy volunteers, 142 significantly changed ions from serum metabolic profile of MG patients were picked out as the potential biomarkers of MG. Among of them, 14 ions were temporarily identified. They were gamma-aminobutyric acid (GABA), pipecolic acid, ornithine, 5,8-tetradecadienoic acid, spermine, hexanoylcarnitine, N-oleoyl glycine, sphingosine-1-phosphate (S1P), bisnorcholic acid, coprocholic acid, phytosphingosine-1-P, chenodeoxycholylglycine, coenzyme Q4, and cholylglycine. The developed OPLS-DA diagnostic model based on the 142 special ions showed a high sensitivity (92.8%) and specificity (83.3%) in detecting MG. QJF showed a powerful action on MG by recovering the holistic serum metabolic profile from the disease level to the normal level. Especially, the levels of GABA, pipecolic acid, ornithine, 5,8-tetradecadienoic acid, spermine, hexanoylcarnitine, N-oleoyl glycine, S1P, bisnorcholic acid, coenzyme Q4, and cholylglycine in MG patients were regulated to a relatively normal level after QJF treatment.
My results first indicated that the LC-FTMS-based metabolomics was a useful tool in biomarkers exploration of MG, and it was potentially applicable as a new diagnostic approach for MG. Also, my results demonstrated that QJF was a good optional choice for the treatment of MG, with no reported side effects.
Detailed summary in vernacular field only.
Detailed summary in vernacular field only.
Detailed summary in vernacular field only.
Detailed summary in vernacular field only.
Lu, Yonghai.
Thesis (Ph.D.)--Chinese University of Hong Kong, 2013.
Includes bibliographical references (leaves 113-129).
Abstract also in Chinese.
Thesis committee --- p.i
Declaration --- p.ii
Abstract (in English) --- p.iii
Abstract (in Chinese) --- p.vi
Acknowledgements --- p.viii
Table of contents --- p.ix
Abbreviations --- p.xiv
List of Tables --- p.xviii
List of Figures --- p.xix
Chapter 1: Introduction --- p.1
Chapter 1.1 --- Myasthenia gravis --- p.1
Chapter 1.1.1 --- History --- p.1
Chapter 1.1.2 --- Epidemiology --- p.2
Chapter 1.1.3 --- Clinical features --- p.2
Chapter 1.1.4 --- Clinical classification --- p.4
Chapter 1.1.5 --- Pathophysiology --- p.5
Chapter 1.1.6 --- Diagnosis --- p.9
Chapter 1.1.6.1 --- Physical examination --- p.9
Chapter 1.1.6.2 --- Blood test --- p.10
Chapter 1.1.6.3 --- Electrodiagnostic test --- p.10
Chapter 1.1.6.4 --- Edrophonium test --- p.11
Chapter 1.1.6.5 --- Imaging --- p.11
Chapter 1.1.6.6 --- Pulmonary function test --- p.11
Chapter 1.1.7 --- Treatment --- p.12
Chapter 1.1.7.1 --- Medication --- p.12
Chapter 1.1.7.2 --- Thymectomy --- p.12
Chapter 1.1.7.3 --- Plasmapheresis and intravenous immunoglobulin --- p.13
Chapter 1.2 --- Qiangji Jianli Fang --- p.14
Chapter 1.2.1 --- Huang qi --- p.15
Chapter 1.2.2 --- Dang shen --- p.16
Chapter 1.2.3 --- Bai shu --- p.16
Chapter 1.2.4 --- Dang gui --- p.17
Chapter 1.2.5 --- Sheng ma --- p.17
Chapter 1.2.6 --- Chai hu --- p.18
Chapter 1.2.7 --- Chen pi --- p.18
Chapter 1.2.8 --- Gan cao --- p.19
Chapter 1.3 --- Metabolomics --- p.19
Chapter 1.3.1 --- What’s metabolomics? --- p.20
Chapter 1.3.1.1 --- Metabolites --- p.20
Chapter 1.3.1.2 --- Metabolome --- p.21
Chapter 1.3.1.3 --- Two terms: metabolomics and metabonomics --- p.21
Chapter 1.3.2 --- How metabolomics works? --- p.22
Chapter 1.3.2.1 --- Sample preparation --- p.22
Chapter 1.3.2.1.1 --- Quenching --- p.23
Chapter 1.3.2.1.2 --- Separating metabolites --- p.24
Chapter 1.3.2.1.3 --- Sample concentration --- p.24
Chapter 1.3.2.2 --- Analytical technologies (Sample analysis) --- p.25
Chapter 1.3.2.3 --- Data analysis --- p.26
Chapter 1.3.2.4 --- Database --- p.28
Chapter 1.3.3 --- Why metabolomics? --- p.29
Chapter 1.3.4 --- Metabolomics for human diseases --- p.30
Chapter 1.3.5 --- Metabolomics for Traditional Chinese Medicine --- p.32
Chapter 1.4 --- Objectives and significances of the present study --- p.34
Chapter Chapter 2 --- Metabolic biomarkers of myasthenia gravis --- p.36
Chapter 2.1 --- Introduction --- p.36
Chapter 2.2 --- Materials and methods --- p.40
Chapter 2.2.1 --- Chemicals --- p.40
Chapter 2.2.2 --- Patients --- p.40
Chapter 2.2.3 --- Volunteers --- p.42
Chapter 2.2.4 --- Blood collection --- p.43
Chapter 2.2.5 --- QC samples --- p.43
Chapter 2.2.6 --- Sample processing --- p.43
Chapter 2.2.7 --- Liquid chromatography-mass spectrometry --- p.44
Chapter 2.2.8 --- Data analysis --- p.45
Chapter 2.2.9 --- Metabolite identification --- p.45
Chapter 2.3 --- Results --- p.46
Chapter 2.3.1 --- Method validation --- p.46
Chapter 2.3.2 --- An overall comparative analysis between 28 patients and 10 volunteers --- p.48
Chapter 2.3.3 --- Classification of MG --- p.53
Chapter 2.3.4 --- Comparative analysis of the metabolic changes in early- and late-stage MG patients respectively --- p.54
Chapter 2.3.5 --- Biomarker identification --- p.56
Chapter 2.4 --- Discussion --- p.58
Chapter 2.5 --- Conclusion --- p.63
Chapter Chapter 3 --- A novel diagnostic approach for myasthenia gravis --- p.64
Chapter 3.1 --- Introduction --- p.64
Chapter 3.2 --- Materials and methods --- p.68
Chapter 3.2.1 --- Chemicals --- p.68
Chapter 3.2.2 --- Patients and Volunteers --- p.69
Chapter 3.2.2.1 --- Training set for establishment of diagnostic model --- p.69
Chapter 3.2.2.2 --- Test set for evaluation of diagnostic model --- p.69
Chapter 3.2.3 --- QC samples --- p.70
Chapter 3.2.4 --- Sample processing --- p.71
Chapter 3.2.5 --- Chromatography --- p.71
Chapter 3.2.6 --- Mass spectrometry --- p.72
Chapter 3.2.7 --- Data analysis --- p.72
Chapter 3.3 --- Results --- p.72
Chapter 3.3.1 --- Method validation --- p.73
Chapter 3.3.2 --- Alterations in serum metabolic profile under MG --- p.74
Chapter 3.3.3 --- Prediction of MG based on biomarkers --- p.74
Chapter 3.3.4 --- Establishment of diagnostic model on the basis of metabolic profile --- p.77
Chapter 3.3.5 --- Prediction of MG with diagnostic model --- p.79
Chapter 3.4 --- Discussion --- p.80
Chapter 3.5 --- Conclusion --- p.83
Chapter Chapter 4 --- Qiangji Jianli Fang treatment for myasthenia gravis --- p.84
Chapter 4.1 --- Introduction --- p.84
Chapter 4.2 --- Materials and methods --- p.88
Chapter 4.2.1 --- Chemicals --- p.88
Chapter 4.2.2 --- Herbs --- p.88
Chapter 4.2.3 --- Participants --- p.88
Chapter 4.2.4 --- QC samples --- p.90
Chapter 4.2.5 --- Sample processing --- p.90
Chapter 4.2.6 --- Liquid chromatography-mass spectrometry --- p.90
Chapter 4.2.7 --- Data analysis --- p.91
Chapter 4.3 --- Results --- p.91
Chapter 4.3.1 --- Method validation --- p.91
Chapter 4.3.2 --- Symptomatic examination after QJF treatment --- p.92
Chapter 4.3.3 --- Holistic metabolic responses to QJF treatment --- p.93
Chapter 4.3.4 --- MG biomarkers changes after QJF treatment --- p.95
Chapter 4.3.5 --- Drug-related biomarkers of QJF --- p.97
Chapter 4.4 --- Discussion --- p.100
Chapter 4.5 --- Conclusion --- p.103
Chapter Chapter 5 --- Conclusions --- p.104
Chapter Chapter 6 --- Perspectives --- p.107
Chapter 6.1 --- Experimental autoimmune myasthenia gravis model --- p.107
Chapter 6.2 --- Chemical composition of Qiangji Jianli Fang --- p.111
References --- p.113
Appendices --- p.130
Books on the topic "Neuromuscular diseases Diagnosis"
E, Knobbout Charlotte, ed. Neuromuscular diseases. Oxford: Oxford University Press, 1987.
Find full textNeuromuscular disorders. Chichester, West Sussex, UK: Wiley-Blackwell, 2011.
Find full textM, Miller Robert. Dysphagia in neuromuscular diseases. San Diego: Plural Publishing, Inc., 2011.
Find full textF, Howard James, and Harper C. Michel, eds. Neuromuscular junction disorders: Diagnosis and treatment. New York: Marcel Dekker, 2004.
Find full textservice), ScienceDirect (Online, ed. Neuromuscular junction disorders. Edinburgh: Elsevier, 2008.
Find full text1941-, Schwartz Martin S., ed. Neuromuscular diseases: A practical approach to diagnosis and management. 3rd ed. London: Springer, 1997.
Find full text1941-, Schwartz Martin S., ed. Neuromuscular diseases: A practical approach to diagnosis and management. 2nd ed. London: Springer-Verlag, 1988.
Find full textS, Schwartz Martin, ed. Neuromuscular diseases: A practical approach to diagnosis and management. 2nd ed. Berlin: Springer-Verlag, 1988.
Find full textAraim, Rawa Jaro. Neuromuscular quick pocket reference. New York: Demos Medical Pub., 2012.
Find full textNeuromuscular disease: Evidence and analysis in clinical neurology. Totowa, N.J: Humana Press, 2006.
Find full textBook chapters on the topic "Neuromuscular diseases Diagnosis"
Venance, Shannon, and Rabi Tawil. "Neuromuscular Diseases: Approach to Clinical Diagnosis." In Neuromuscular Disorders, 1–5. Oxford, UK: Wiley-Blackwell, 2011. http://dx.doi.org/10.1002/9781119973331.ch1.
Full textAlpert, Jack N. "Neuromuscular Diseases: Neuroanatomic and Differential Diagnoses." In The Neurologic Diagnosis, 289–345. Cham: Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-319-95951-1_9.
Full textAlpert, Jack N. "Neuromuscular Diseases: Neuroanatomic and Differential Diagnoses." In The Neurologic Diagnosis, 179–205. New York, NY: Springer New York, 2011. http://dx.doi.org/10.1007/978-1-4419-6724-4_9.
Full textSperl, Wolfgang, Daniela Skladal, Erich Gnaiger, Markus Wyss, Udo Mayr, Josef Hager, and Frank Norbert Gellerich. "High resolution respirometry of permeabilized skeletal muscle fibers in the diagnosis of neuromuscular disorders." In Detection of Mitochondrial Diseases, 71–78. Boston, MA: Springer US, 1997. http://dx.doi.org/10.1007/978-1-4615-6111-8_11.
Full textAlmoallim, Hani, Hadiel Albar, and Fahtima Mehdawi. "Diagnostic Approach to Proximal Myopathy." In Skills in Rheumatology, 191–207. Singapore: Springer Singapore, 2021. http://dx.doi.org/10.1007/978-981-15-8323-0_9.
Full textBenatar, Michael. "Diagnosis." In Neuromuscular Disease, 13–19. Totowa, NJ: Humana Press, 2006. http://dx.doi.org/10.1007/978-1-59745-106-2_2.
Full textMiranda, A. F., T. Mongini, E. Bonilla, A. D. Miller, and W. E. Wright. "Myogenic Conversion of Human Non-Muscle Cells for the Diagnosis and Therapy of Neuromuscular Diseases." In Myoblast Transfer Therapy, 205–10. Boston, MA: Springer US, 1990. http://dx.doi.org/10.1007/978-1-4684-5865-7_23.
Full textAgius, Mark A., David P. Richman, and Angela Vincent. "Autoantibody Testing in the Diagnosis and Management of Autoimmune Disorders of Neuromuscular Transmission and Related Diseases." In Myasthenia Gravis and Related Disorders, 143–56. Totowa, NJ: Humana Press, 2008. http://dx.doi.org/10.1007/978-1-59745-156-7_9.
Full textAgius, Mark A., David P. Richman, and Angela Vincent. "Specific Antibodies in the Diagnosis and Management of Autoimmune Disorders of Neuromuscular Transmission and Related Diseases." In Myasthenia Gravis and Related Disorders, 177–96. Totowa, NJ: Humana Press, 2003. http://dx.doi.org/10.1007/978-1-59259-341-5_8.
Full textCao, Michelangelo, and Angela Vincent. "Autoantibody Testing in the Diagnosis and Management of Autoimmune Disorders of Neuromuscular Transmission and Related Diseases." In Myasthenia Gravis and Related Disorders, 153–68. Cham: Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-319-73585-6_10.
Full textConference papers on the topic "Neuromuscular diseases Diagnosis"
Horvath, Rita. "Mitochondrial Diseases: Diagnosis and Novel Approach for Treatment." In Congenital Dystrophies - Neuromuscular Disorders Precision Medicine: Genomics to Care and Cure. Hamad bin Khalifa University Press (HBKU Press), 2020. http://dx.doi.org/10.5339/qproc.2020.nmd.18.
Full textSadi-Ahmed, Nafissa, Anis Messekher, Salim Namane, Malika Kedir-Talha, and Slimane Mekaoui. "Automatic diagnosis of neuromuscular diseases from electromyographic (EMG) records." In 2017 5th International Conference on Electrical Engineering - Boumerdes (ICEE-B). IEEE, 2017. http://dx.doi.org/10.1109/icee-b.2017.8192195.
Full textStraub, Volker. "The Role of Magnetic Resonance Imaging in the Diagnosis and Assessment of Patients with Genetic Muscle Diseases." In Congenital Dystrophies - Neuromuscular Disorders Precision Medicine: Genomics to Care and Cure. Hamad bin Khalifa University Press (HBKU Press), 2020. http://dx.doi.org/10.5339/qproc.2020.nmd.7.
Full textSomani, Vikas, A. Nisam Rahman, Devvret Verma, Radha Raman Chandan, R. G. VIdhya, and Vinodh P. Vijayan. "Classification of Motor Unit Action Potential Using Transfer Learning for the Diagnosis of Neuromuscular Diseases." In 2022 8th International Conference on Smart Structures and Systems (ICSSS). IEEE, 2022. http://dx.doi.org/10.1109/icsss54381.2022.9782209.
Full textPinto, Wladimir Bocca Vieira de Rezende, Paulo Victor Sgobbi de Souza, Paulo Roberto Abrão Ferreira, Igor Braga Farias, José Marcos Vieira de Albuquerque Filho, Roberta Ismael Lacerda Machado, Bruno de Mattos Lombardi Badia, Márcio Luiz Escórcio Bezerra, Marcus Vinícius Magno Gonçalves, and Acary Souza Bulle Oliveira. "Post-COVID-19 mononeuritis multiplex: a potential complication in severe SARS-CoV- 2 infection survivors." In XIII Congresso Paulista de Neurologia. Zeppelini Editorial e Comunicação, 2021. http://dx.doi.org/10.5327/1516-3180.030.
Full textGoker, Imran, M. Baris Baslo, N. Gorkem Sirin, and A. Emre Oge. "Development of a Method to Analyze Compound Action Potential (CMAP) Scan Used in the Diagnosis and Monitoring of Neuromuscular Diseases." In 2018 Medical Technologies National Congress (TIPTEKNO). IEEE, 2018. http://dx.doi.org/10.1109/tiptekno.2018.8597153.
Full textVenture, Gentiane, Yoshihiko Nakamura, Katsu Yamane, and Masaya Hirashima. "A Painless and Constraint-free Method to Estimate Viscoelastic Passive Dynamics of Limbs' Joints to Support Diagnosis of Neuromuscular Diseases." In 2007 29th Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE, 2007. http://dx.doi.org/10.1109/iembs.2007.4353553.
Full textMoreira, Isabelle Caroline Fasolo Normandia, Rie Tiba Maglioni, Renata Dal Prá Ducci, Cláudia Suemi Kamoi Kay, Otto Jesus Hernandez Fustes, Lineu César Werneck, Paulo José Lorenzoni, and Rosana Hermínia Scola. "Epidemiological profile of myasthenia gravis patients at the Neuromuscular Diseases Service of the Hospital de Clínicas of the Federal University of Paraná." In XIII Congresso Paulista de Neurologia. Zeppelini Editorial e Comunicação, 2021. http://dx.doi.org/10.5327/1516-3180.152.
Full textCamelo Filho, Antonio Edvan, Diego Sant’Ana Sodré, Halisson Flamini Arantes, and Carlos Otto Heise. "Covid-19 Brachial plexopathy: a case report." In XIII Congresso Paulista de Neurologia. Zeppelini Editorial e Comunicação, 2021. http://dx.doi.org/10.5327/1516-3180.518.
Full textPinto, Wladimir Bocca Vieira de Rezende, Bruno de Mattos Lombardi Badia, Igor Braga Farias, José Marcos Vieira de Albuquerque Filho, Roberta Ismael Lacerda Machado, Paulo Victor Sgobbi de Souza, and Acary Souza Bulle Oliveira. "Expanding the neurological and imaging phenotype of women with adult-onset X- linked Adrenoleukodystrophy." In XIII Congresso Paulista de Neurologia. Zeppelini Editorial e Comunicação, 2021. http://dx.doi.org/10.5327/1516-3180.019.
Full text